Alessandro Vatrella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1564345/publications.pdf

Version: 2024-02-01

148 papers

4,521 citations

87723 38 h-index 60 g-index

150 all docs

150 docs citations

150 times ranked

5775 citing authors

#	Article	IF	CITATIONS
1	Biologics in severe asthma. Minerva Medica, 2022, 113, .	0.3	15
2	Effectiveness of benralizumab in severe eosinophilic asthma: Distinct subâ€phenotypes of response identified by cluster analysis. Clinical and Experimental Allergy, 2022, 52, 312-323.	1.4	19
3	Prevalence of Persistent Olfactory Disorders in Patients With COVIDâ€19: A Psychophysical Caseâ€Control Study With 1â€Year Followâ€up. Otolaryngology - Head and Neck Surgery, 2022, 167, 183-186.	1.1	37
4	Post-COVID-19 Syndrome: Involvement and Interactions between Respiratory, Cardiovascular and Nervous Systems. Journal of Clinical Medicine, 2022, 11, 524.	1.0	73
5	Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets. Frontiers in Pharmacology, 2022, 13, 851940.	1.6	41
6	Novel Biological Therapies for Severe Asthma Endotypes. Biomedicines, 2022, 10, 1064.	1.4	10
7	Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines, 2022, 10, 974.	2.1	7
8	Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease. Respiration, 2021, 100, 127-134.	1.2	10
9	Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression. Journal of Asthma and Allergy, 2021, Volume 14, 163-173.	1.5	39
10	Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies. Drug Design, Development and Therapy, 2021, Volume 15, 1275-1284.	2.0	32
11	Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. International Journal of Molecular Sciences, 2021, 22, 3059.	1.8	36
12	Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma. International Journal of Molecular Sciences, 2021, 22, 4369.	1.8	33
13	Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4371-4380.e4.	2.0	37
14	Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma. Biomedicines, 2021, 9, 1108.	1.4	24
15	Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis. Journal of Asthma and Allergy, 2021, Volume 14, 1165-1172.	1.5	31
16	Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma. Biomedicines, 2021, 9, 1550.	1.4	11
17	Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis., 2021, , .		O
18	DPO: DIFFUSE PULMONARY OSSIFICATION - A DIAGNOSTIC CHALLENGE. Translational Medicine @ UniSa, 2021, 24, .	0.8	O

#	Article	IF	CITATIONS
19	Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN- \hat{l}^2 but Higher Levels of IL- $1\hat{l}_2$ and TGF- \hat{l}^2 . Biomedicines, 2021, 9, 1931.	1.4	49
20	New treatments for asthma: From the pathogenic role of prostaglandin D2 to the therapeutic effects of fevipiprant. Pharmacological Research, 2020, 155, 104490.	3.1	20
21	Molecular Targets for Biological Therapies of Severe Asthma. Frontiers in Immunology, 2020, 11, 603312.	2.2	65
22	REAL-LIFE TREATMENT OF SEVERE EOSINOPHILIC ASTHMA WITH BENRALIZUMAB. Chest, 2020, 157, A6.	0.4	1
23	Posttranscriptional Gene Regulatory Networks in Chronic Airway Inflammatory Diseases: In silico Mapping of RNA-Binding Protein Expression in Airway Epithelium. Frontiers in Immunology, 2020, 11, 579889.	2.2	6
24	Pharmacotherapeutic strategies for critical asthma syndrome: a look at the state of the art. Expert Opinion on Pharmacotherapy, 2020, 21, 1505-1515.	0.9	2
25	Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study. Frontiers in Pharmacology, 2020, 11, 857.	1.6	105
26	Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662093350.	1.0	101
27	Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma. SAGE Open Medical Case Reports, 2020, 8, 2050313X2090696.	0.2	17
28	Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomedicine and Pharmacotherapy, 2020, 129, 110444.	2,5	29
29	Phenotyping severe asthma: a rationale for biologic therapy. Expert Review of Precision Medicine and Drug Development, 2020, 5, 265-274.	0.4	6
30	Role of p38-mitogen-activated protein kinase in COPD: pathobiological implications and therapeutic perspectives. Expert Review of Respiratory Medicine, 2020, 14, 485-491.	1.0	30
31	Clinical relevance of understanding mitogen-activated protein kinases involved in asthma. Expert Review of Respiratory Medicine, 2020, 14, 501-510.	1.0	20
32	Correlation between work impairment, scores of rhinitis severity and asthma using the MASKâ€air [®] App. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1672-1688.	2.7	32
33	Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy. , 2020, , .		1
34	Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101830.	1.1	44
35	Early management of COPD: where are we now and where do we go from here? A Delphi consensus project /p>. International Journal of COPD, 2019, Volume 14, 353-360.	0.9	11
36	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. Journal of Allergy and Clinical Immunology, 2019, 143, 864-879.	1.5	103

3

#	Article	IF	Citations
37	Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study. Pulmonary Pharmacology and Therapeutics, 2019, 54, 25-30.	1.1	33
38	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (<scp>MACVIA</scp> â€ <scp>ARIA</scp>) ― <scp>EIP</scp> on <scp>AHA</scp> Twinning Reference Site (<scp>GARD</scp> research demonstration project). Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 77-92.	2.7	54
39	Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children. Expert Opinion on Biological Therapy, 2018, 18, 197-204.	1.4	17
40	Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661881019.	1.0	93
41	Differential expression of RNA-binding proteins in bronchial epithelium of stable COPD patients. International Journal of COPD, 2018, Volume 13, 3173-3190.	0.9	18
42	SIRT1 Activity in Peripheral Blood Mononuclear Cells Correlates with Altered Lung Function in Patients with Chronic Obstructive Pulmonary Disease. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-8.	1.9	22
43	Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. BioMed Research International, 2018, 2018, 1-9.	0.9	81
44	Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Design, Development and Therapy, 2018, Volume 12, 619-628.	2.0	46
45	Obesity and respiratory function impairment in asthmatic and non asthmatic children. , 2018, , .		0
46	Long-term treatment in pediatric asthma: an update on chemical pharmacotherapy. Expert Opinion on Pharmacotherapy, 2017, 18, 667-676.	0.9	10
47	Fine-needle cytology in the follow-up of breast carcinoma. Aging Clinical and Experimental Research, 2017, 29, 167-171.	1.4	3
48	Neither walking test performance nor fatty liver suggest altered respiratory function in obese children assessed by appropriate spirometry percentiles. Digestive and Liver Disease, 2017, 49, e250.	0.4	0
49	Dupilumab for the treatment of asthma. Expert Opinion on Biological Therapy, 2017, 17, 1565-1572.	1.4	33
50	Validation of the <scp>MASK</scp> â€rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. Clinical and Experimental Allergy, 2017, 47, 1526-1533.	1.4	75
51	Surgical approach in thymectomy: Our experience and review of the literature. International Journal of Surgery Case Reports, 2017, 39, 19-24.	0.2	21
52	Asthma: Targeted Biological Therapies. , 2017, , .		3
53	Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Design, Development and Therapy, 2017, Volume 11, 3137-3144.	2.0	70
54	Airway Remodelling in Asthma. , 2017, , 17-25.		3

#	Article	IF	CITATIONS
55	Anti-IL-4/IL-13 Biologics. , 2017, , 67-81.		1
56	The reversed halo sign: also think about chronic eosinophilic pneumonia. Jornal Brasileiro De Pneumologia, 2017, 43, 322-323.	0.4	2
57	Anti-lgE Therapy. , 2017, , 27-49.		0
58	Conclusions and Future Perspectives. , 2017, , 97-99.		0
59	Anti-TNF-α Therapies. , 2017, , 83-87.		0
60	Other Biologic Drugs. , 2017, , 93-96.		0
61	IL-5-Targeted Antibodies., 2017,, 51-66.		0
62	Inflammatory Cellular Patterns in Asthma. , 2017, , 5-15.		0
63	Biologic Treatments Targeted to Innate Cytokines. , 2017, , 89-91.		0
64	Allergenic Pollen and Pollen Allergy in Europe. , 2017, , 261-279.		1
65	SIRT 1 and oxidative stress in COPD pathogenesis. , 2017, , .		0
66	Role of the inflammasome in idiopathic pulmonary fibrosis. , 2017, , .		0
67	Impact of long-term treatment with inhaled corticosteroids and bronchodilators on lung function in a patient with post-infectious bronchiolitis obliterans. Jornal Brasileiro De Pneumologia, 2016, 42, 228-231.	0.4	10
68	Fractional exhaled nitric oxide-measuring devices: technology update. Medical Devices: Evidence and Research, 2016, 9, 151.	0.4	42
69	Climate Change and Air Pollution: Effects on Respiratory Allergy. Allergy, Asthma and Immunology Research, 2016, 8, 391.	1.1	146
70	Role of biologics in severe eosinophilic asthma & Dinical Risk Management, 2016, Volume 12, 1075-1082.	0.9	43
71	Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma. Pulmonary Pharmacology and Therapeutics, 2016, 40, 15-21.	1.1	29
72	Idiopathic pleural panniculitis with recurrent pleural effusion not associated with Weber-Christian disease. Open Medicine (Poland), 2016, 11, 394-398.	0.6	1

#	Article	IF	CITATIONS
73	Thunderstormâ€related asthma: what happens and why. Clinical and Experimental Allergy, 2016, 46, 390-396.	1.4	124
74	Cushing's like syndrome in typical bronchial carcinoid a case report and review of the literature. International Journal of Surgery Case Reports, 2016, 20, 1-4.	0.2	2
75	Abdominal adiposity is an early marker of pulmonary function impairment: Findings from a Mediterranean Italian female cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 643-648.	1.1	29
76	Role of FDG-PET scan in staging of pulmonary epithelioid hemangioendothelioma. Open Medicine (Poland), 2016, 11, 158-162.	0.6	12
77	Answers Regarding the Etiology of Severe Community-Acquired Pneumonia: Usefulness of Polymerase Chain Reaction Techniques. Respiration, 2016, 92, 285-285.	1.2	0
78	Asthma-related deaths. Multidisciplinary Respiratory Medicine, 2016, 11, 37.	0.6	100
79	Diagnostic yield and safety of C-TBNA in elderly patients with lung cancer. Open Medicine (Poland), 2016, 11, 477-481.	0.6	8
80	The impact of social and digital media on asthmatic adolescents. Pediatric Allergy and Immunology, 2016, 27, 650-651.	1.1	2
81	The diagnostic accuracy of fine-needle cytology of Hurthle cell lesions; A comprehensive cytological, clinical and ultrasonographic experience. International Journal of Surgery, 2016, 28, S65-S69.	1.1	6
82	Pituitary dysfunction and its association with quality of life in traumatic brain injury. International Journal of Surgery, 2016, 28, S103-S108.	1.1	9
83	Surgical management of cervico-mediastinal goiters: Our experience and review of the literature. International Journal of Surgery, 2016, 28, S47-S53.	1.1	45
84	Intranasal budesonide improves quality of life in patient with COPD and chronic nasal symptoms. , 2016, , .		0
85	Latent tuberculosis infection (LTBI): a real host defence or a permanent threat?. Infezioni in Medicina, 2016, 24, 179-82.	0.7	0
86	Pulmonary arterovenous malformation causing hemothorax in a pregnant woman without Osler-Weber-Rendu syndrome. Open Medicine (Poland), 2015, 10, 549-554.	0.6	5
87	Effects on asthma and respiratory allergy of Climate change and air pollution. Multidisciplinary Respiratory Medicine, 2015, 10, 39.	0.6	92
88	Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD. Therapeutics and Clinical Risk Management, 2015, 11, 1563.	0.9	16
89	Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma. Mediators of Inflammation, 2015, 2015, 1-8.	1.4	167
90	Sirtuin 1 and Aging Theory for Chronic Obstructive Pulmonary Disease. Analytical Cellular Pathology, 2015, 2015, 1-8.	0.7	48

#	Article	IF	CITATIONS
91	Extended analysis of exhaled and nasal nitric oxide for the evaluation of chronic cough. Respiratory Medicine, 2015, 109, 970-974.	1.3	35
92	Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting \hat{l}^2 2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment. Expert Opinion on Pharmacotherapy, 2015, 16, 2009-2021.	0.9	20
93	Non respiratory symptoms in asthma as possible predictors of exacerbations. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 798-800.e2.	2.0	10
94	Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments. Current Drug Targets, 2015, 16, 171-178.	1.0	24
95	Dupilumab: a novel treatment for asthma. Journal of Asthma and Allergy, 2014, 7, 123.	1.5	99
96	Application of Proteomics and Peptidomics to COPD. BioMed Research International, 2014, 2014, 1-8.	0.9	31
97	COPD: maximization of bronchodilation. Multidisciplinary Respiratory Medicine, 2014, 9, 50.	0.6	17
98	Age as a risk factor in the occurrence of pneumothorax after transthoracic fine needle biopsy: Our experience. International Journal of Surgery, 2014, 12, S29-S32.	1.1	12
99	Post-pneumonectomy broncho-pleural fistula successfully closed by open-window thoracostomy associated with V.A.C. therapy. International Journal of Surgery, 2014, 12, S17-S19.	1.1	13
100	Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review. Multidisciplinary Respiratory Medicine, 2014, 9, 23.	0.6	62
101	Neuroendocrine differentiation in breast carcinoma with osteoclast-like giant cells. Report of a case and review of the literature. International Journal of Surgery, 2014, 12, S8-S11.	1.1	4
102	Bone and soft tissue non-Hodgkin lymphoma of the maxillofacial area: Report of two cases, literature review and new therapeutic strategies. International Journal of Surgery, 2014, 12, S23-S28.	1.1	12
103	Recumbent deoxygenation in mild/moderate liver cirrhosis: the "Clinodeoxia― The ortho-clino paradigm. Respiratory Medicine, 2014, 108, 1040-1048.	1.3	2
104	Small cell lung cancer associated with solitary fibrous tumors of the pleura: A case study and literature review. International Journal of Surgery, 2014, 12, S19-S21.	1.1	6
105	Extrathoracic recurrence of type A thymoma. International Journal of Surgery, 2014, 12, S16-S18.	1.1	9
106	Detection of RAS mutation by pyrosequencing in thyroid cytology samples. International Journal of Surgery, 2014, 12, S91-S94.	1.1	18
107	Recurrent respiratory infections caused by a double aortic arch: TheÂdiagnostic role of spirometry. Respiratory Medicine Case Reports, 2013, 8, 47-50.	0.2	7
108	Update on Anticytokine Treatment for Asthma. BioMed Research International, 2013, 2013, 1-10.	0.9	55

#	Article	IF	CITATIONS
109	The potential of biologics for the treatment of asthma. Nature Reviews Drug Discovery, 2012, 11, 958-972.	21.5	201
110	Effects of statins and farnesyl transferase inhibitors on <scp>ERK</scp> phosphorylation, apoptosis and cell viability in nonâ€small lung cancer cells. Cell Proliferation, 2012, 45, 557-565.	2.4	65
111	Non invasive ventilation away from ICU. Translational Medicine @ UniSa, 2012, 2, 64-5.	0.8	0
112	Update on optimal use of omalizumab in management of asthma. Journal of Asthma and Allergy, 2011, 4, 49.	1.5	51
113	T Cell Activation State in the Induced Sputum of Asthmatics Treated with Budesonide. International Journal of Immunopathology and Pharmacology, 2010, 23, 745-753.	1.0	6
114	Imbalance of circulating dendritic cell subsets in chronic obstructive pulmonary disease. Clinical Immunology, 2010, 137, 102-110.	1.4	23
115	Interleukinâ€6 receptor superantagonist Sant7 inhibits TGFâ€Î²â€induced proliferation of human lung fibroblasts. Cell Proliferation, 2008, 41, 393-407.	2.4	37
116	Increased activation of p38 MAPK in COPD. European Respiratory Journal, 2008, 31, 62-69.	3.1	230
117	Molecular mechanisms underlying airway smooth muscle contraction and proliferation: Implications for asthma. Respiratory Medicine, 2008, 102, 1173-1181.	1.3	86
118	Induced sputum as a tool for early detection of airway inflammation in connective diseases-related lung involvement. Respiratory Medicine, 2007, 101, 1383-1389.	1.3	16
119	Effects of TGF- \hat{l}^2 and glucocorticoids on map kinase phosphorylation, IL-6/IL-11 secretion and cell proliferation in primary cultures of human lung fibroblasts. Journal of Cellular Physiology, 2007, 210, 489-497.	2.0	50
120	Respiratory infections and asthma. Respiratory Medicine, 2006, 100, 775-784.	1.3	48
121	Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction. Respiratory Medicine, 2006, 100, 1415-1422.	1.3	48
122	Biological targets for therapeutic interventions in COPD: clinical potential. International Journal of COPD, 2006, 1, 321-334.	0.9	8
123	Endothelin-1 induces proliferation of human lung fibroblasts and IL-11 secretion through an ETA receptor-dependent activation of map kinases. Journal of Cellular Biochemistry, 2005, 96, 858-868.	1.2	48
124	Mitogen-activated protein kinases and asthma. Journal of Cellular Physiology, 2005, 202, 642-653.	2.0	92
125	An Acute Bronchodilator Test with Tiotropium or Salmeterol Does Not Allow a Subdivision of Patients according to Responses. Respiration, 2005, 72, 466-470.	1.2	8
126	Bronchodilating effects of salmeterol, theophylline and their combination in patients with moderate to severe asthma. Pulmonary Pharmacology and Therapeutics, 2005, 18, 89-92.	1.1	18

#	Article	IF	Citations
127	Comparative Effects of a Two-Week Treatment with Nebivolol and Nifedipine in Hypertensive Patients Suffering from COPD. Respiration, 2004, 71, 159-164.	1.2	21
128	Effects of hydrogen peroxide on MAPK activation, IL-8 production and cell viability in primary cultures of human bronchial epithelial cells. Journal of Cellular Biochemistry, 2004, 93, 142-152.	1.2	45
129	Potential genetic influences on the response to asthma treatment. Pulmonary Pharmacology and Therapeutics, 2004, 17, 253-261.	1.1	10
130	Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sciences, 2003, 72, 1549-1561.	2.0	88
131	Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler. Pulmonary Pharmacology and Therapeutics, 2003, 16, 105-109.	1.1	9
132	Effects of Transforming Growth Factor- \hat{l}^2 and Budesonide on Mitogen-Activated Protein Kinase Activation and Apoptosis in Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 12-18.	1.4	53
133	Comparison of the Bronchodilating Effects of Inhaled Formoterol, Salmeterol and Salbutamol in Asthmatic Patients. Pulmonary Pharmacology and Therapeutics, 2002, 15, 463-466.	1.1	15
134	A single-blind, partial crossover clinical trial of the effects of inhaled fluticasone propionate and nedocromil sodium on airway hyperresponsiveness to methacholine. Current Therapeutic Research, 2002, 63, 316-327.	0.5	1
135	Potential role of potassium channel openers in the treatment of asthma and chronic obstructive pulmonary disease. Life Sciences, 2002, 70, 977-990.	2.0	52
136	Inhaled Ultrasonically Nebulized Distilled Water Decreases Exhaled Nitric Oxide in Asthma. Lung, 2002, 180, 319-326.	1.4	2
137	PASSIVE SMOKE AND EXHALED NITRIC OXIDE. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1188-1188.	2.5	4
138	Exhaled nitric oxide after inhalation of isotonic and hypotonic solutions in healthy subjects. Clinical Science, 2001, 101, 645-650.	1.8	11
139	Exhaled nitric oxide after inhalation of isotonic and hypotonic solutions in healthy subjects. Clinical Science, 2001, 101, 645.	1.8	8
140	Effect of inhaled heparin on water-induced bronchoconstriction in allergic asthmatics. European Journal of Clinical Pharmacology, 2001, 57, 5-9.	0.8	15
141	Effects of non-bronchoconstrictive doses of inhaled propranolol on airway responsiveness to methacholine. European Journal of Clinical Pharmacology, 2001, 57, 99-104. Effects of glucocorticoids on activation of c-jun N-terminal, extracellular signal-regulated, and p38	0.8	15
142	MAP kinases in human pulmonary endothelial cellsâ€â€Abbreviations: AP-1, activator protein-1; Dex, dexamethasone; ERK, extracellular signal-regulated kinases; GCS, glucocorticosteroids; GR, glucocorticoid receptors; H2O2, hydrogen peroxide; HMVEC-L, human microvascular endothelial cells from lung; IL-1β, interleukin-1β; JNK, c-jun N-terminal kinases; MAPK, mitogen-activated protein kinases;	2.0	26
143	Test testosterone;. Biochemical Pharmacology, 2001, 62, 1719-1724. Serum eosinophil cationic protein (ECP) as a marker of disease activity and treatment efficacy in seasonal asthma. Allergy: European Journal of Allergy and Clinical Immunology, 1996, 51, 547-555.	2.7	24
144	Effects on asthma and respiratory allergy of Climate change and air pollution. Multidisciplinary Respiratory Medicine, 0, 10 , .	0.6	6

#	Article	IF	CITATIONS
145	Asthma-related deaths. Multidisciplinary Respiratory Medicine, 0, 11, .	0.6	13
146	COPD: maximization of bronchodilation. Multidisciplinary Respiratory Medicine, 0, 9, .	0.6	0
147	Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review. Multidisciplinary Respiratory Medicine, 0, 9, .	0.6	O
148	Activation of the AIM2 Receptor in Circulating Cells of Post-COVID-19 Patients With Signs of Lung Fibrosis Is Associated With the Release of IL-11 \pm , IFN-1 \pm and TGF-1 \pm . Frontiers in Immunology, 0, 13, .	2.2	10